Jun 20, 2020
Glenmark Becomes the First Pharmaceutical Company in India to Receive Regulatory Approval for Oral Antiviral Favipiravir, for the Treatment of Mild to Moderate COVID-19
May 26, 2020
Glenmark to Commence New Phase 3 Clinical Trial on Combination of Two Anti-viral Drugs Favipiravir and Umifenovir in Hospitalized Patients of Moderate COVID-19 in India
May 12, 2020
Glenmark Initiates Phase 3 Clinical Trials on Antiviral Favipiravir for COVID-19 Patients in India
Apr 29, 2020
Pipeline Insights for Seasonal Allergic Rhinitis, with Coverage of Allergy Therapeutics, Glenmark Pharmaceutical and VentiRx Pharmaceuticals
Feb 27, 2020
Hikma and Glenmark Pharmaceuticals Enter into Exclusive Licensing Agreement for Commercialising Ryaltris(TM) Seasonal Allergic Rhinitis Nasal Spray in the US
Feb 25, 2020
Neuraxpharm Reinforces Presence in Poland
May 02, 2019
Glenmark Therapeutics Expands Specialty Portfolio with OTIPRIO® Co-Promotion Agreement in the U.S. with Otonomy for Acute Otitis Externa Indication
Mar 01, 2019
Glenmark Pharmaceuticals Announces Presentation of New Subtype Analysis of GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at the American Academy of Dermatology Annual Meeting
Feb 25, 2019
Glenmark Pharmaceuticals Announces Results from New Analysis of Pooled Data on Ryaltris(TM), an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, at the AAAAI 2019 Annual Meeting
Feb 19, 2019
Glenmark Pharmaceuticals to Present New Analysis of Pooled Data on Ryaltris(TM), an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, at the AAAAI 2019 Annual Meeting
Dec 14, 2018
Glenmark Pharmaceuticals Announces New Data on GBR 1302, a HER2xCD3 Bispecific Antibody, Presented at the ESMO Immuno-Oncology Congress 2018
Nov 15, 2018
Glenmark Pharmaceuticals Announces New Data Presentations on Ryaltris(TM) at the ACAAI Annual Scientific Meeting 2018
Nov 07, 2018
Glenmark Pharmaceuticals Announces Decision to Launch Phase 1 Trial in Solid Tumors for its CD38xCD3 Bispecific Antibody GBR 1342 Based on Human Translational Data
Oct 30, 2018
Glenmark Pharmaceuticals Celebrates the Inauguration of its U.S. Manufacturing Site in Monroe, North Carolina
Sep 12, 2018
Mitra Biotech Announces Partnership with Glenmark Pharmaceuticals to Provide Clinically Relevant Translational Platform Supporting Development of Immuno-Oncology Portfolio
Aug 07, 2018
Glenmark Pharmaceuticals Announces FDA Acceptance of the Company's First New Drug Application for Ryaltris(TM) for Patients with Seasonal Allergic Rhinitis
Jun 18, 2018
The US FDA Approves First Supplemental Abbreviated New Drug Application (sANDA) for Glenmark Pharmaceuticals' Manufacturing Facility in Monroe, North Carolina
May 21, 2018
Glenmark Pharmaceuticals Announces the Company's First New Drug Application for Ryaltris(TM) for Patients with Seasonal Allergic Rhinitis
May 17, 2018
Glenmark Pharmaceuticals Announces Oral Presentation of New Data on GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at the International Investigative Dermatology Meeting
Apr 16, 2018
Glenmark Pharmaceuticals Announces Initiation of a Phase 2b Trial of GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis